Many people with inflammatory bowel disease (IBD) are told to “feed their gut bacteria” or eat more fibre, without ever being told why. One of the clearest answers lies in a single molecule produced during digestion: butyrate. Understanding what it does helps explain why diet, the gut lining, and inflammation are so closely linked.
What is butyrate?
Butyrate is a short-chain fatty acid (SCFA), a small fat molecule made when gut bacteria ferment fibre that the small intestine cannot digest. It is produced mainly in the colon by specific bacterial groups, including species from the Firmicutes family, as they break down resistant starches, inulin, and other plant fibres. Alongside acetate and propionate, butyrate is one of the three main SCFAs, but it is the one most closely tied to the health of the gut lining itself.
Why it matters for gut inflammation
The colon lining is made of a single layer of cells called colonocytes, which form a barrier between gut contents and the immune system underneath. Butyrate is the preferred fuel source for these cells, meaning they rely on it for energy more than on sugar from the bloodstream. When butyrate supply is low, colonocytes can become energy-starved, the barrier may weaken, and bacterial components can come into closer contact with immune cells in the gut wall. This process is thought to contribute to the ongoing low-level immune activation seen in IBD, where the boundary between gut contents and the immune system becomes less controlled.
Key mechanisms
Fuelling the gut lining
Colonocytes get up to the majority of their daily energy from butyrate rather than glucose. This is unusual compared with most cells in the body and reflects how specialised the colon lining is. In active Crohn’s disease and ulcerative colitis, studies have shown reduced numbers of butyrate-producing bacteria, which may leave colonocytes under-fuelled at a time when the lining is already under strain from inflammation.
Strengthening the gut barrier
Butyrate supports the production of proteins that hold neighbouring colonocytes tightly together, forming what is often called the tight junction network. A well-maintained barrier limits the movement of bacteria and bacterial fragments from the gut into the tissue below. When this barrier becomes more permeable, sometimes referred to as increased intestinal permeability, it can make it easier for the immune system to be triggered inappropriately.
Calming immune signalling
Butyrate interacts with immune cells in the gut wall, including a type of white blood cell called a regulatory T cell, which helps dampen unnecessary immune responses. By supporting these regulatory pathways, butyrate may help reduce the production of pro-inflammatory signalling molecules called cytokines. This does not mean butyrate switches off inflammation entirely, but it may help the immune system maintain a more balanced, less reactive state in the gut.
Shaping the microbial environment
Butyrate production also depends on a stable, diverse microbiome, the community of bacteria living in the gut. A lower diversity microbiome, which is commonly observed in people with IBD, tends to produce less butyrate overall. This creates a pattern where inflammation and reduced microbial diversity can reinforce each other, rather than a simple one-way cause and effect.
Supporting mucus layer production
The colon lining is also protected by a mucus layer that acts as a physical buffer against bacteria. Butyrate has been shown to support mucus-producing cells, helping maintain this protective layer. A thinner or disrupted mucus layer has been observed in some studies of ulcerative colitis, suggesting this mechanism may be particularly relevant for that condition.
It is important to be clear that butyrate is one piece of a much larger picture. IBD is caused by a combination of genetic, immune, and environmental factors, and symptoms do not always correspond directly to the level of inflammation present. Nutritional strategies that support butyrate production should never be used to replace prescribed IBD medication, and any dietary changes, especially increasing fibre during a flare, should be discussed with a gastroenterologist or dietitian, since fibre tolerance can vary significantly during active disease.
Practical Takeaways
- Focus on consistent, gradual fibre intake rather than large sudden increases, particularly when transitioning out of a flare.
- Include a variety of plant fibre sources where tolerated, such as oats, cooked vegetables, and legumes, to support diverse butyrate-producing bacteria.
- Avoid assuming that absence of symptoms means absence of inflammation, or that symptoms always mean active disease.
- Discuss fibre and fermented food changes with a dietitian familiar with IBD, especially during periods of active inflammation or stricturing disease.
- Keep any supplement or dietary change as one part of an overall plan agreed with your IBD team, not a replacement for medication.
Conclusion
Butyrate illustrates how closely diet, the microbiome, and gut immune activity are connected in IBD. It will not resolve inflammation on its own, but understanding its role helps explain why consistent, individualised dietary approaches are often emphasised alongside medical treatment. Long-term stability in the gut environment, rather than short-term fixes, is generally far more useful for managing inflammatory load over time. Any changes to diet should be made gradually and in partnership with a healthcare professional.
References
- Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21(9):793-798. doi:10.1136/gut.21.9.793
- Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104-119. doi:10.1111/j.1365-2036.2007.03562.x
- Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275-1283. doi:10.1136/gutjnl-2013-304833
- Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9(3):309-313. doi:10.1111/j.1365-2036.1995.tb00386.x
- Venegas DP, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. doi:10.3389/fimmu.2019.00277
- Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19(1):29-41. doi:10.1111/1462-2920.13589
- Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. Dig Dis Sci. 1996;41(11):2254-2259. doi:10.1007/BF02071409
- Peng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619-1625. doi:10.3945/jn.109.104638
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.